Marked weight loss in a type 2 diabetic patient treated with acarbose [1]

Diabetes Care

Volumn 22, Issue 4, 1999, Pages 645-646

  Yoo, Wan Hee ^a,b   Park, Tae Sun ^a   Baek, Hong Sun ^a  

^a Chonbuk National University Medical School and Hospital   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADULT; CASE REPORT; CLINICAL FEATURE; DIABETES CONTROL; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0033001085     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.4.645     Document Type: Letter

References (13)

1. Hanefeld M: The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:228-237, 1998
2. Caspary W: Diabetes mellitus: verzoperung der Kohlenhydrat-Resorption als therapeutisches Prinzip. Heft 19:1413-1423, 1985
3. Clissold SP, Edwards C: Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentials. Drugs 35:214-243, 1988
4. Wolever TMS, Chiasson JL, Josse RG, Ilunt IA, Palmason C, Rodger NW, Ross SA, Ryan SA, Tan MH: Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes 21:756-763, 1997
5. Hitoshi I: The antiobesity action of (S)-(+)-1-(4-chlorophenylthiomethyl)-N-methylethylamine fumarate (AO-124). Eur J Pharmacol 124:201-210, 1986
6. Tuomilehto J, Pohjola M, Lindstrom J, Aro A: Acarbose and nutrient intake in non-insulin-dependent diabetes mellitus. Diab Res Clin Prac 26:215-222, 1994
7. Sailer D, Roeder G: Treatment of non-insulin-dependent diabetic adults with a new glycoside hydrolase inhibitor (Baylor 5421). Arzneimittel-Forschung 30:2182-2185, 1980
8. Tulp OL, Michaelis OE, Stevens C: Effects of acarbose on food intake, plasma lipid profiles, and glycemic parameters in male and female Wistar Fatty rats. In New Models of Genetically Obese Rats for Studies in Diabetes, Heart Disease and Complications of Obesity. Veterinary Resources Branch, NIH publication, Bethesda, MD, 1988, p. 203-209
9. Maury J, Issad T, Perdereau D, Gouhot B, Ferre P, Girard J: Effect of acarbose on glucose homeostasis, lipogenesis and lipogenic enzyme gene expression in adipose tissue of weaned rats. Diabetologia 36:503-509, 1993
10. Lembcke B: Therapieprinzip Resorptionsverzogerung: Wirkprinzip a-Glukosidase-Inhibition. Berlin, Springer-Verlag, 1991
11. Suehiro I, Otsuki M, Yamasaki T: Effect of α-glucosidase inhibitor on human pancreatic and salivary amylase. Clin Chim Acta 117:145-152, 1981
12. Vasselli JR, Haraczkiewicz E, Maggio CA, Greenwood MR: Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats. Pharmacol Biochem Behav 19:85-95, 1983
13. Wolever TMS, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH: One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 12:164-172, 1995